, Tracking Stock Market Picks
Enter Symbol:
E-z-em, Inc. (EZEM) [hlAlert]

up 2.53 %

E-z-em, Inc. (EZEM) rated Buy

Posted on: Wednesday,  Oct 31, 2007  11:25 AM ET by CL King

CL King rated Buy E-z-em, Inc. (EZEM) on 10/31/2007, when the stock price was $20.48. Since then,
E-z-em, Inc. has gained 2.54% as of 05/16/2008's recent price of $21.00.
If you would have followed this CL King's recommendation on EZEM, you would have gained 2.53% of your investment in 198 days.

E-Z-EM Inc. is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company recently introduced VoLumen the next generation low density barium sulfate suspension for use as an oral contrast in Multidetector CT and Positron Emission Tomography studies. The Company also offers Empower the only family of CT injectors on the market with patented EDA technology that can help detect contrast extravasation and offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents & a carbon dioxide colon insufflation system. The Company is also the exclusive world-wide manufacturer and marketer of RSDL for first-responder organizations & military services. RSDL is a patented, broad-spectrum liquid chemical warfare agent decontaminant, that neutralizes or removes chemical agents from skin on contact, leaving a non-toxic residue that can be rinsed off with water.

CL King research analysts "Discover the Uncovered." Our analysts seek out small- and mid-cap companies that may be ignored by other Wall Street research providers, identifying value and growth that may be unrecognized by institutional equity investors. Our goal is to generate superior absolute returns while minimizing downside risk.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/31/2007 11:25 AM Buy
as of 5/23/2009
1 Week   
1 Month   
3 Months   
1 YTD up  1.30 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy